Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesFirebrick Pharma Ltd

Firebrick Pharma Ltd

Healthcare Drug Manufacturers - General
PortfolioPortfolio WatchlistWatchlist
Company price
0.031 AUD 0.00 ( 6.90%)
Last update at 2026-11-12T04:40:00Z
VOLUME
339262
Market Cap
8.63M

Momentum Score

…

Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.03
Low
0.03
High
52 Week Price Range
0.02
Low
0.07
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Firebrick Pharma Ltd is an Australian-listed pharmaceutical company with limited public disclosures; available materials indicate it is a development-stage drug company but detailed pipeline information is scarce. Its long-term prospects may depend on advancement of any clinical programs, regulatory approvals and strategic partnerships, and investors may find potential upside if those milestones are achieved and commercial pathways are established.

The primary investment risks include development and regulatory setbacks, constrained access to capital with potential dilution, limited liquidity as a small-cap listing and uncertain commercial viability for any eventual products.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.03
Dividend Yield
-
Revenue TTM
0.14M
Revenue Per Share
0.00
Gross Profit TTM
-0.03M
Debt / Equity
-
ROE
-189.19%
Net Debt
-1.32M
ROCE
-184.42%
Diluted EPS TTM
-0.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax -3.09M -2.63M -1.18M -6.80M -3.80M
Net income -3.06M -2.63M -1.18M -6.80M -3.80M
Selling general administrative - 0.30M 0.22M 2.76M 0.50M
Selling and marketing expenses - 0.74M 0.26M - 0.33M
Gross profit -1.04M 0.10M -0.02M 0.00M 0.00M
Reconciled depreciation - 0.01M 0.01M 0.01M 0.01M
Ebit -3.10M -2.87M -1.17M -6.75M -3.79M
Ebitda -3.10M -2.86M -1.17M -6.85M -3.79M
Depreciation and amortization 0.00M 0.01M 0.01M - 0.01M
Operating income -3.10M -2.87M -3.93M -6.86M -3.79M
Other operating expenses 3.21M 3.16M 3.94M 0.19M 4.88M
Interest expense - 0.01M 0.00M - 0.00M
Tax provision - 0.00M 0.00M 0.00M 0.00M
Interest income - 0.01M 0.02M 0.04M 0.00M
Net interest income - 0.01M 0.02M 0.04M -0.00M
Income tax expense -0.03M -0.22M -2.74M - 1.08M
Total revenue 0.11M 0.29M 0.01M 0.00M 0.00M
Total operating expenses 2.07M 2.97M 3.90M - 4.88M
Cost of revenue 1.14M 0.19M 0.04M - -
Total other income expense net 0.01M 0.23M 2.75M 0.02M 1.08M
Net income from continuing ops - -2.63M -1.18M -6.80M -3.80M
Net income applicable to common shares - -2.63M -1.18M -6.80M -3.80M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 2.17M 1.83M 2.41M 2.98M 8.73M
Other current assets 0.12M 0.05M 0.08M 0.10M 0.01M
Total liab 0.48M 0.27M 0.29M 0.51M 0.45M
Total stockholder equity 1.68M 1.56M 2.12M 2.48M 8.28M
Other current liab 0.28M - 0.22M 0.17M 0.41M
Common stock 22.67M - 17.88M 17.07M 16.00M
Capital stock - 19.90M - 17.07M 16.00M
Retained earnings -21.55M -18.79M -16.51M -15.58M -8.81M
Other assets - - 0.00M 0.36M 0.36M
Cash 1.32M 0.98M 0.82M 2.35M 7.14M
Total current liabilities 0.48M 0.27M 0.29M 0.51M 0.45M
Net debt -1.32M - -0.82M - -7.14M
Short term debt - - - 0.00M 0.00M
Other stockholder equity - - - 0.99M 1.08M
Property plant equipment - - - 0.03M 0.04M
Total current assets 1.86M 1.48M 2.09M 2.59M 8.33M
Net tangible assets - - - 2.48M 8.28M
Net receivables 0.05M 0.01M 0.95M 0.14M 1.08M
Inventory 0.36M 0.19M 0.24M - 0.10M
Accounts payable 0.20M 0.11M 0.07M 0.20M 0.04M
Accumulated other comprehensive income 0.56M - 0.74M - 1.08M
Non currrent assets other 0.19M 0.25M 0.29M 0.36M 0.36M
Non current assets total 0.31M 0.34M 0.31M 0.39M 0.40M
Long term debt total - - - 0.00M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - -0.08M -0.00M -0.00M -0.03M
Change to liabilities - - - 0.06M 0.20M
Total cashflows from investing activities - -0.08M -0.00M -0.00M -0.03M
Total cash from financing activities 2.94M 2.02M 0.82M 1.00M 10.23M
Change to operating activities - - - 0.01M -0.05M
Net income -3.06M -2.63M -1.18M -6.80M -3.80M
Change in cash 0.34M 0.16M -1.53M -4.79M 5.99M
Begin period cash flow 0.98M 0.82M 2.35M 7.14M 1.15M
End period cash flow 1.32M 0.98M 0.82M 2.35M 7.14M
Total cash from operating activities -2.60M -1.78M -2.34M -5.78M -4.20M
Issuance of capital stock - 1.93M 0.82M 1.00M 10.70M
Depreciation 0.00M - 0.01M 0.01M 0.01M
Change to inventory -0.13M 0.03M -0.17M - -0.28M
Change to account receivables 0.21M 0.69M -0.81M 0.94M -0.58M
Sale purchase of stock - -0.03M -0.01M 1.00M -0.47M
Other cashflows from financing activities - 0.12M -0.00M -0.01M 0.11M
Change to netincome - - - 0.00M 0.30M
Capital expenditures 0.00M 0.08M 0.00M 0.00M 0.03M
Change in working capital 0.23M 0.78M -1.18M -4.25M -2.81M
Stock based compensation - - -0.00M - -
Other non cash items 0.23M -2.56M -0.24M - -
Free cash flow -2.60M -1.86M -2.35M -5.78M -0.03M

Peer Comparison*

Sector: Healthcare Industry: Drug Manufacturers - General

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
FRE
Firebrick Pharma Ltd		 0.00
6.90%		 0.03 - - 63.61 5.13 68.90 -8.09

Profile*

Firebrick Pharma Ltd

Firebrick Pharma Limited develops and commercializes povidone-iodine (PVP-I) products under the Nasodine brand in Asia, North America, Europe, and internationally. It offers nasal and throat spray PVP-I products for the treatment of common cold. The company was incorporated in 2012 and is based in Melbourne, Australia.

Level 14, Melbourne, VIC, Australia

61 1 300 301 874

https://firebrickpharma.com

Name Title Year Born
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Exec. Chairman & CEO 1954
Dr. Stephen Francis Goodall MASc, MBA Founder, COO & Exec. Director NA
Mr. Kavi Bekarma B.Sc., C.A. Chief Financial Officer NA
Dr. Simon Tucker Chief Scientific Officer NA
Ms. Robyn Branigan Head of Marketing NA
Prof. Peter Friedland Chief Medical Officer NA
Dr. Monique Baldwin Head of Regulatory Affairs NA
Ms. Kyla Garic Exec. Officer NA
Mr. Stephen Buckley Company Sec. NA
Dr. Peter Laurence Molloy BSc, FAICD, MBA Founder, Executive Chairman & CEO 1954

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…